Market Place
Sourcing Support
Kura Announces Positive Results from Registration-Directed Study of Tipifarnib
17 Oct 2023 //
GLOBENEWSWIRE
Kura Oncology drops multiple clinical programs for J&J-discovered tipifarnib
24 Feb 2023 //
ENDPTS
Kura Reports Proof of Mechanism in Phase 1/2 Trial of Tipifarnib & Alpelisib
26 Oct 2022 //
GLOBENEWSWIRE
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib
16 Dec 2021 //
GLOBENEWSWIRE
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib
13 Dec 2021 //
GLOBENEWSWIRE
Kura Oncology Announces Publication of Tipifarnib Ph2 Data
23 Mar 2021 //
GLOBENEWSWIRE
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal
22 Mar 2021 //
GLOBENEWSWIRE
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib
24 Feb 2021 //
PRESS RELEASE
Kura Oncology Reports Preclinical Results Showing Antitumor of Tipifarnib
26 Oct 2020 //
GLOBENEWSWIRE
Kura flashes positive HRAS data on once-failed J&J drug
30 May 2020 //
ENDPTS
Antonio Gualberto starts post-Kura career at Eisai subsidiary H3
22 Feb 2020 //
ENDPTS
Kura Oncology Establishes Collaboration With Foundation Medicine Tipifarnib Dep
18 Jul 2017 //
DDDMAG
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.